drugset / Trial / NCT01673984
GP Extended Action Triptorelin
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to demonstrate that treatment with a 6-monthly injection of hormone therapy is as good and as well tolerated as the standard 3-monthly hormone therapy injections available for treating prostate cancer. The study will also aim to answer whether both doctors and patients would prefer treatment with a 6-monthly injection rather than injections every 3 months.
Timeline
- Start
- 2012-08
- Primary completion
- 2014-02
- Completion
- 2014-02
Outcome
Outcome not reported
Stopped: “The study was discontinued prematurely by the sponsor due to non-medical reasons”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Prostap® 3 DCS | Unknown | 11.25 mg | Subcutaneous |
| Subject | Triptorelin | Other / unclassified | 11.25 mg | Intramuscular |
| Subject | Triptorelin | Other / unclassified | 22.5 mg | Intramuscular |
| Comparator | Zoladex® LA | Unknown | 10.8 mg | Subcutaneous |